EU-X-CT Public Stakeholders' Forum 2024
Making cross-border access to clinical trials a reality
The pan-European public-private EU-X-CT Initiative aims at facilitating cross-border access to clinical trials in concrete terms. We are collecting information on the regulatory, ethical, healthcare system and organizational conditions for the involved stakeholders, experiences and best practices in all European countries. This Public Stakeholders' Forum will be the opportunity to jointly review the national conditions for patients, clinical investigators, academia/public funders and industry sponsors in need for cross-border participation of patients in clinical trials. The EU-X-CT gap analysis will be the basis for our panel and open forum discussions to come to conclusions about most efficient European and national strategies and activities for improvements in the near and mid-term future.
Cannot join us on site? Follow this event online for free, please register by clicking HERE.
*Disclaimer: by attending the workshop for free via Zoom, it is not guaranteed that you will be able to interact directly with the Faculty.
With the Support of
Programme
| 09:00 |
Registration and welcome coffee |
|
Session 1: Where are we today? |
|
| 10:00 |
Introduction to EU-X-CT |
|
Welcome from EFGCP and EFPIA
Ingrid Klingmann, Pharmaplex, EFGCP
Susan Bhatti, Merck BV, Chair CREG (EFPIA)
|
|
|
Welcome from the academia members
Jacques Demotes Mainard, ECRIN
|
|
|
Welcome from the patient members
Lisbeth Snede, Patient Unite
|
|
| 10:20 |
Round table: Current experience with cross-border trial participation Moderator(s): Lisbeth Snede, Patient Unite
Michel Zwaan, Prinses Máxima Centrum voor kinderoncologie BV
Violeta Astratinei, Melanoma Patient Network Europe
|
| 10:50 |
Keynote: Overcoming borders will make Europe a more attractive place for clinical trials
Elmar Nimmesgern, EU Commission DG R&I
|
| 11:20 |
The issues of cross-border access to clinical trials in Europe: The EU-X-CT gap analysis Moderator(s): Susan Bhatti, Merck BV
Lisbeth Snede, Patient unite
Maja Pizevska, Berlin Institute of Health at Charité (BIH)
Maren Koban, Merck Healthcare KGaA
|
| 12:20 |
Panel and Open Forum Discussion:
• Is this picture accurate and comprehensive?
• Where are the assessment gaps?
• How to close them?
• Which other EU partnerships suffer from the lack of cross-border access to clinical trials? Moderator(s): Solange Corriol-Rohou, AstraZeneca
Elmar Nimmesgern, EU Commission DG R&I
Emilie Prazakova, Roche
Janek Kapper, Estonian Inflammatory Bowel Disease Society
Marianne Lunzer, AGES, CTCG co-chair
Michel Zwaan, Prinses Máxima Centrum voor kinderoncologie BV
Monique Al, CCMO, CTCG co-chair, MedEthicsEU co-chair
|
| 13:00 |
Lunch |
|
Session 2: Where do we want to go? |
|
| 14:00 |
Enabling cross-border access to Clinical Trial Moderator(s): Sabine Kläger, ECRIN
Bettina Ryll, Stockholm School of Economics Institute for Research
Joanna Sprague, ICON
|
| 14:30 |
The way forward: how do we make progress in cross-border access to Clinical Trials? Moderator(s): Bettina Ryll, Stockholm School of Economics Institute for Research
Begonya Nafria Escalera, Hospital San Juan de Déu, eYPAGnet
Elmar Nimmesgern, EU Commission DG R&I
Jacques Demotes Mainard, ECRIN
Marianne Lunzer, AGES, CTCG co-chair
Monique Al, CCMO, CTCG co-chair, MedEthicsEU co-chair
Susan Bhatti, Merck BV
|
| 15:30 |
Break |
| 15:50 |
Open Forum Discussion: How can EU-X-CT achieve the most urgent goals and how to make them sustainable? Moderator(s): Ingrid Klingmann, Pharmaplex, EFGCP Susan Bhatti, Merck BV |
| 16:50 |
Conclusions and next steps Moderator(s): Ingrid Klingmann, Pharmaplex, EFGCP |
| 17:00 |
End of meeting |